ZA200308341B - Crystal Forms of Azithromycin. - Google Patents
Crystal Forms of Azithromycin. Download PDFInfo
- Publication number
- ZA200308341B ZA200308341B ZA200308341A ZA200308341A ZA200308341B ZA 200308341 B ZA200308341 B ZA 200308341B ZA 200308341 A ZA200308341 A ZA 200308341A ZA 200308341 A ZA200308341 A ZA 200308341A ZA 200308341 B ZA200308341 B ZA 200308341B
- Authority
- ZA
- South Africa
- Prior art keywords
- azithromycin
- ppm
- peaks
- water
- theta
- Prior art date
Links
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims description 224
- 229960004099 azithromycin Drugs 0.000 title claims description 223
- 239000013078 crystal Substances 0.000 title claims description 67
- 238000001228 spectrum Methods 0.000 claims description 39
- 239000000126 substance Substances 0.000 claims description 39
- VQEMDSRIOVZAOM-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CSC(N)=N1 VQEMDSRIOVZAOM-UHFFFAOYSA-N 0.000 claims description 28
- 229960004924 azithromycin dihydrate Drugs 0.000 claims description 28
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- 208000015181 infectious disease Diseases 0.000 description 47
- 238000000634 powder X-ray diffraction Methods 0.000 description 40
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 35
- 239000007787 solid Substances 0.000 description 32
- 239000000843 powder Substances 0.000 description 29
- 239000002904 solvent Substances 0.000 description 27
- 238000000034 method Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 20
- 238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 238000001144 powder X-ray diffraction data Methods 0.000 description 14
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 14
- 239000012453 solvate Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000002002 slurry Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 208000035143 Bacterial infection Diseases 0.000 description 11
- 208000022362 bacterial infectious disease Diseases 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 238000002425 crystallisation Methods 0.000 description 10
- 230000008025 crystallization Effects 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- HQUPLSLYZHKKQT-WVVFQGGUSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-o Chemical compound O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 HQUPLSLYZHKKQT-WVVFQGGUSA-N 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000606856 Pasteurella multocida Species 0.000 description 9
- 229960003256 azithromycin monohydrate Drugs 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 238000002447 crystallographic data Methods 0.000 description 9
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 8
- 239000003120 macrolide antibiotic agent Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 230000018044 dehydration Effects 0.000 description 7
- 238000006297 dehydration reaction Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 241000251468 Actinopterygii Species 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229960004063 propylene glycol Drugs 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004807 desolvation Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000003828 vacuum filtration Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 241001293418 Mannheimia haemolytica Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 150000004683 dihydrates Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 229940041033 macrolides Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 150000004682 monohydrates Chemical group 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008261 resistance mechanism Effects 0.000 description 3
- -1 sachets Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000006104 solid solution Substances 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241001148536 Bacteroides sp. Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 238000004497 NIR spectroscopy Methods 0.000 description 2
- 241000191992 Peptostreptococcus Species 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241001312524 Streptococcus viridans Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000005384 cross polarization magic-angle spinning Methods 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001148534 Brachyspira Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241001518260 Corynebacterium minutissimum Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 241000605721 Dichelobacter nodosus Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 101100119095 Enterococcus faecalis (strain ATCC 700802 / V583) ermB gene Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000605952 Fusobacterium necrophorum Species 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 241001148567 Lawsonia intracellularis Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 101150052154 MSRA1 gene Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000010315 Mastoiditis Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000588622 Moraxella bovis Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000513886 Mycobacterium avium complex (MAC) Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241001138504 Mycoplasma bovis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 101001041669 Oryctolagus cuniculus Corticostatin 1 Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 241000566150 Pandion haliaetus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 241000756999 Potamogetonaceae Species 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 108010015795 Streptogramin B Proteins 0.000 description 1
- 108010034396 Streptogramins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- 101000870345 Vasconcellea cundinamarcensis Cysteine proteinase 1 Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940092524 bartonella henselae Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Chemical group 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 101150016744 ermC gene Proteins 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 208000010801 foot rot Diseases 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- YUWFEBAXEOLKSG-UHFFFAOYSA-N hexamethylbenzene Chemical compound CC1=C(C)C(C)=C(C)C(C)=C1C YUWFEBAXEOLKSG-UHFFFAOYSA-N 0.000 description 1
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000012844 infrared spectroscopy analysis Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 101150111763 mefA gene Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 101150021123 msrA gene Proteins 0.000 description 1
- 101150114366 msrA2 gene Proteins 0.000 description 1
- 101150006794 msrAB gene Proteins 0.000 description 1
- 101150109310 msrAB1 gene Proteins 0.000 description 1
- 101150052209 msrAB2 gene Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- YGXCETJZBDTKRY-DZCVGBHJSA-N pristinamycin IA Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-DZCVGBHJSA-N 0.000 description 1
- CIBMHJPPKCXONB-UHFFFAOYSA-N propane-2,2-diol Chemical compound CC(C)(O)O CIBMHJPPKCXONB-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940041030 streptogramins Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000004457 water analysis Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Description
Crystal Forms of Azithromycin
This invention relates to crystal forms of azithromycin. Azithromycin is sold commercially and is an effective antibiotic in the treatment of a broad range of bacterial infections. The crystal forms of this invention are likewise useful as antibiotic agents in mammals, including man, as well as in fish and birds.
Azithromycin has the following structural formula:
H,C, _CH,
HC CH, Ho, N
H,C., N OH : " ent O CH, ~~ HO7 ~=CH; ch,
H,C Ou, °°
H,C © CH, "OH 0 HC 9
CH,
Azithromycin is described and claimed in United States Patents 4,517,359 and 4,474,768. [tis also known as 9-deoxo-9a-aza-9a-methyi-9a-homoerythomycin A.
Other patents or patent applications which directly or indirectly cover azithromycin include: EP 298,650 which claims azithromycin dihydrate; U.S. Patent 4,963,531 which claims a method of treating a strain of Toxoplasma gondii species; U.S. Patent 5,633,006 which claims a chewable tablet or liquid suspension pharmaceutical composition having reduced bitterness; U.S. Patent 5,686,587 which claims an intermediate useful in the preparation of azithromycin; U.S. Patent 5,605,889 which claims an oral dosage form that reduces the “food effect” associated with the administration of azithromycin; U.S. Patent 6,068,859 which claims a controlled dosage form containing azithromycin; U.S. Patent 5,498,699 which claims a composition containing azithromycin in combination with bivalent or trivalent metals; EP 925,789 which claims a method of treating eye infections; Chinese patent application CN 1123279A which relates to water soluble salts of azithromycin; Chinese patent application CN 1046945C which relates to azithromycin sodium dihydrogenphosphate double salts; Chinese patent application CN 1114960A which relates to azithromycin crystals, Chinese patent application CN 1161971A which relates to azithromycin crystals; Chinese patent application
CN 1205338A which relates to a method of preparing water soluble salts of azithromycin;
International Publication WO 00/32203 which relates to an ethanolate of azithromycin; and
European patent application EP 984,020 which relates to an azithromycin monohydrate isopropanol clathrate.
The present invention relates to crystal forms of azithromycin. As used herein, the term “crystal form(s)” or “form(s)’, unless otherwise noted, means one or more crystal forms of azithromycin. )
In particular, the present invention relates to a crystal form of azithromycin wherein said crystal form is selected from forms C, D, E, F, G, H, J, M, N, O, P, Q and R wherein said forms are as defined herein. Forms F, G, H, J, M, N, O, and P belong to family | azithromycin and belong to a monoclinic P2, space group with cell dimensions of a = 16.3+0.3 A, b = 16.2+0.3 A, ¢c = 18.4+0.3 A and beta = 109 + 2°. Forms C, D, E and R belong to family I azithromycin and belong to an orthorhombic P2, 2,2, space group with cell dimensions of a = 8.9+0.4 A, b=12.320.5Aand c = 45.8:0.5 A. Form Q is distinct from families ! and N.
Form F azithromycin is of the formula CazsH7oN2042°H20+0.5C.HsOH in the single crystal structure, being azithromycin monohydrate hemi-ethanol solvate. Form F is further characterized as containing 2-5% water and 1-4% ethanol by weight in powder samples and having powder X-ray diffraction 26 peaks as defined in Table 9. The °C ssNMR (solid state
Nuclear Magnetic Resonance) spectrum of form & has two chemical shift peaks at approximately 179+1 ppm, those being 179.5+0.2 ppm and 178.6+0.2 ppm, a set of five peaks between 6.4 to 11.0 ppm, and ethanol peaks at 58.0£0.5 ppm and 17.2+0.5 ppm. The solvent peaks can be broad and relatively weak in intensity.
The invention also relates to substantially pure form F azithromycin, form F azithromycin substantially free of form G azithromycin and form F azithromycin substantially free of azithromycin dihydrate.
The invention further relates to methods of preparing form F azithromycin by treating azithromycin with ethanol to complete dissolution at 40-70°C and cooling with reduction of ethanol or addition of water to effect crystallization. Also included are methods of making substantially pure form F azithromycin, form F azithromycin substantially free of form G azithromycin and form F azithromycin substantially free of azithromycin dihydrate.
Form G azithromycin is of the formula CagH72N204201.5H,0 in the single crystal structure, being azithromycin sesquihydrate. Form G is further characterized as containing 2.5-6% water and <1 % organic solvent(s) by weight in powder samples and having powder
X-ray diffraction 26 peaks as defined in Table 9. The *C ssNMR spectrum of form G has one chemical shift peak at approximately 179+1 ppm, being a peak at 179.5£0.2 ppm (splitting <0.3 ppm may present), and a set of five peaks between 6.3 to 11.0 ppm.
The invention also relates to substantially pure form G azithromycin, and form G azithromycin substantially free of azithromycin dihydrate.
The invention further relates to methods of preparing substantially pure form G azithromycin, and form G azithromycin substantially free of azithromycin dihydrate by treating azithromycin with a mixture of methanol and water or acetone and water to complete dissolution at 40-60°C and cooling to effect crystallization.
Form H azithromycin is of the formula CagHz,N2042°H,0°C3HgO, being azithromycin monohydrate hemi-1,2 propanediol solvate.
Form J azithromycin is of the formula CzgH7N,O422H,0°0.5C3H;OH in the single crystal structure, being azithromycin monohydrate hemi-n-propanol solvate. Form J is further characterized as containing 2-5% water and 1-5% 1-propanol by weight in powder samples and having powder X-ray diffraction 20 peaks as defined in Table 9. The 3C ssNMR spectrum of form J has two chemical shift peaks at approximately 179+1 ppm, those being 179.6+0.2 ppm and 178.4+0.2 ppm, a set of five peaks between 6.6 to 11.7 ppm and an n- propanol peak at 25.2£0.4 ppm. The solvent peak can be broad and relatively weak in intensity.
The invention further relates to methods of preparing form J by treating azithromycin with n-propanol to complete dissolution at 25-55°C and cooling with addition of water to effect crystallization.
Form M azithromycin is of the formula CaiH72N20O422H,0-0.5C3H;OH, being azithromycin monohydrate hemi-isopropanol solvate. Form M is further characterized as containing 2-5% water and 1-4% 2-propanol by weight in powder samples and having powder
X-ray diffraction 26 peaks as defined in Table 9. The °C ssNMR spectrum of form M has one chemical shift peak at approximately 179+1 ppm, being 179.620.2 ppm, a peak at 41.91+0.2 ppm and a set of six peaks between 6.9 to 16.4 ppm and an isopropanol peak at 26.0£0.4 ppm. The solvent peak can be broad and relatively weak in intensity. "The invention also relates to substantially pure form M azithromycin, form M azithromycin substantially free of form G azithromycin and form M azithromycin substantially free of azithromycin dihydrate.
The invention further relates to methods of preparing substantially pure form M azithromycin, form M azithromycin substantially free of form G azithromycin and form M azithromycin substantially free of azithromycin dihydrate by treating azithromycin with isopropanol to complete dissolution at 40-60°C and reduction of isopropanol followed by cooling or cooling followed by addition of water to effect crystallization.
Form N azithromycin is a mixture of isomorphs of Family I. The mixture may contain variable percentages of isomorphs, F, G, H, J, M and others, and variable amounts of water and organic solvents, such as ethanol, isopropanol, n-propanol, propylene glycol, acetone, acetonitrile, butanol, pentanol, etc. The weight percent of water can range from 1-5% and the total weight percent of organic solvents can be 2-5% with each solvent content of 0.5 to 4%.
The samples of form N display all characteristic peaks of members of Family | in various proportions. Form N may be characterized as ‘mixed crystals’ or “crystalline solid solutions’ of
Family | isomorphs. :
Form N displays chemical shifts as a combination of isomorphs in Family I. The peaks may vary in chemical shift ppm within + 0.2 ppm and in relative intensities and width due to the mixing of variable proportion of isomorphs contained in the form N crystalline solid solution.
Form P azithromycin is of the formula CazH7N20412°H,0+0.5C:H,0 being azithromycin monohydrate hemi-n-pentanol solvate.
Form Q azithromycin is of the formula C35H72N,0422H,0+0.5C4HsO being azithromycin monohydrate hemi-tetrahydrofuran solvate.
Form R azithromycin is of the formula CagH72N,042*H>0*CsH 20 being azithromycin monohydrate mono-methyl tert-butyl ether solvate.
Form D azithromycin is of the formula CgzsH7oN,0422H,0+CeHy, in its single crystal structure, being azithromycin monohydrate monocyclohexane solvate. Form D is further characterized as containing 2-6% water and 3-12% cyclohexane by weight in powder samples and having representative powder X-ray diffraction 26 peaks as defined in Table 9.
The °C ssNMR spectrum of form D displays has one chemical shift peak at approximately 179+1ppm, being 178.1£0.2ppm and peaks at 103.920.2ppm, 95.1+0.2ppm, 84.2+0.2ppm, and a set of 3 peaks between 8.4 to 11 ppm.
The invention further relates to methods of preparing form D by slurrying azithromycin dihydrate with cyclohexane.
Form E azithromycin is of the formula CzsH72N;O12°H20+C4HsO being azithromycin monchydrate mono-tetrahydrofuran solvate.
The invention further relates to azithromycin in an amorphous state and a method of preparing amorphous azithromycin that comprises the removal of water and/or solvents from the azithromycin crystal lattice. The X-ray diffraction powder pattern for amorphous azithromycin displays no sharp 26 peaks but has two broad rounded peaks. The first peak occurs between 4° and 13°. The second peak occurs between 13° and 25°.
The invention also relates to pharmaceutical compositions for the treatment of a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises a therapeutically effective amount of the crystalline compounds referred to above, or amorphous azithromycin, and a pharmaceutically acceptable carrier.
The invention also relates to a method of treating a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises administering to said mammal, fish or bird a therapeutically effective amount of the crystalline compounds referred to above, or amorphous azithromycin.
The present invention also relates to methods of preparing crystal forms of azithromycin which comprise the slurrying of azithromycin in an appropriate solvent or the dissolution of azithromycin in a heated organic solvent or organic solvent/water solution and precipitating the crystalline azithromycin by cooling the solution with reduction of solvent volume or by dissolving azithromycin in a solvent or solvent mixture and precipitating crystalline azithromycin by the addition of water to the solution. Azithromycin in amorphous state is prepared by heating crystalline azithromycin in a vacuum.
The term “treatment”, as used herein, unless otherwise indicated, means the treatment or prevention of a bacterial infection or protozoa infection as provided in the method of the present invention, including curing, reducing the symptoms of or slowing the progress of said infection. The terms “treat” and “treating” are defined in accord the foregoing term “treatment”.
The term "substantially free” when referring to a designated crystalline form of azithromycin means that there is less than 20% (by weight) of the designated crystalline form(s) present, more preferably, there is less than 10% (by weight) of the designated form(s) present, more preferably, there is less than 5% (by weight) of the designated form(s) present, and most preferably, there is less than 1% (by weight) of the designated crystalline form(s) present. For instance, form F azithromycin substantially free of azithromycin dihydrate means form F with 20% (by weight) or {ess of azithromycin dihydrate, more preferably, 10% (by weight) or less of azithromycin dihydrate, most preferably, 1% (by weight) of azithromycin dihydrate.
The term “substantially pure” when referring to a designated crystalline form of azithromycin means that the designated crystalline form contains less than 20% (by weight) of residual components such as alternate polymorphic or isomorphic crystalline form(s) of azithromycin. It is preferred that a substantially pure form of azithromycin contain less than 10% (by weight) of alternate polymorphic or isomorphic crystalline forms of azithromycin, more preferred is less than 5% (by weight) of alternate polymorphic or isomorphic crystalline forms of azithromycin, and most preferably less than 1% (by weight) of alternate polymorphic or isomorphic crystalline forms of azithromycin. - 30 The term “substantially in the absence of azithromycin dihydrate” when referring to bulk crystalline azithromycin or a composition containing crystalline azithromycin means the crystalline azithromycin contains less than about 5% (by weight) azithromycin dihydrate, more preferabiy iess han about 3% (Dy weight) azithwormycin dinydraie, and mosi preferably ess than 1% (by weight) azithromycin dihydrate.
As used herein, unless otherwise indicated, the term “bacterial infection(s)" or “protozoa infection” includes bacterial infections and protozoa infections and diseases caused by such infections that occur in mammals, fish and birds as well as disorders related to bacterial infections and protozoa infections that may be treated or prevented by administering antibiotics such as the compound of the present invention. Such bacterial infections and protozoa infections and disorders related to such infections include, but are not limited to, the following: pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis,
Staphylococcus aureus, or Peptostreptococcus spp.; pharynigitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Clostridium diptheriae, or Actinobacillus haemolyticum; respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila,
Streptococcus pneumoniae, Haemophilus influenzae, or Chlamydia pneumoniae; uncomplicated skin and soft tissue infections, abscesses and osteomyelitis, and puerperal : fever related to infection by Staphylococcus aureus, coagulase-positive staphylococci (i.e., S. epidermidis, S. hemolyticus, efc.), Streptococcus pyogenes , Streptococcus agalactiae,
Streptococcal groups C-F (minute-colony streptococci), viridans streptococci,
Corynebacterium minutissimum, Clostridium spp., or Bartonella henselae; uncomplicated acute urinary tract infections related to infection by Staphylococcus saprophyticus or
Enterococcus spp.; urethritis and cervicitis; and sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Neiserria gonorrheae; toxin diseases related to infection by S. aureus (food poisoning and Toxic shock syndrome), or Groups A, B, and C streptococci; ulcers related to infection by Helicobacter pylori; systemic febrile syndromes related to infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorferi; conjunctivitis, keratitis, and dacrocystitis related to infection by Chlamydia trachomatis, Neisseria gonorrhoeae, S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, or Listeria spp.; disseminated
Mycobacterium avium complex (MAC) disease related to infection by Mycobacterium avium, or Mycobacterium intracellulare; gastroenteritis related to infection by Campylobacter jejuni; intestinal protozoa related to infection by Cryptosporidium spp.; odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by Bordetella pertussis; gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.; and atherosclerosis related to infection by Helicobacter pylori or Chlamydia pneumoniae.
Also included are atherosclerosis and malaria. Bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in animals include, but are not limited to, the following: bovine respiratory disease related to infection by P. haem., P. multocida, Mycoplasma bovis, or Bordetella spp.; cow enteric disease related to infection by E. coli or protozoa (i.e., coccidia, cryptosporidia, etc.); dairy cow mastitis related to infection by Staph. aureus, Strep. uberis, Strep. agalactiae, Strep. dysgalactiae, Klebsiella spp., Corynebacterium, or Enterococcus spp.; swine respiratory disease related to infection oo by A. pleuro., P. multocida, or Mycoplasma spp.; swine enteric disease related to infection by
E. coli, Lawsonia intracellularis, Salmonella, or Serpulina hyodyisinteriae; cow footrot related to infection by Fusobacterium spp.; cow metritis related to infection by E. coli; cow hairy warts related to infection by Fusobacterium necrophorum or Bacteroides nodosus, cow pink-eye related to infection by Moraxella bovis; cow premature abortion related to infection by protozoa (i.e. neosporium); urinary tract infection in dogs and cats related to infection by E. coli; skin and soft tissue infections in dogs and cats related to infection by Staph. epidermidis,
Staph. intermedius, coagulase neg. Staph. or P. multocida; and dental or mouth infections in dogs and cats related to infection by Alcaligenes spp., Bacteroides spp., Clostridium spp.,
Enterobacter spp., Eubacterium, Peptostreptococcus, Porphyromonas, or Prevotella. Other bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in accord with the method of the present invention are referred to in J.
P. Sanford et al., “The Sanford Guide To Antimicrobial Therapy,” 26th Edition, (Antimicrobial
Therapy, Inc., 1996).
The present invention also includes isotopically-labeled compounds wherein one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as %H, °H, °C, *C, **N, "*0, and "70.
Such radiolabelled and stable-isotopically labelled compounds are useful as research or diagnostic tools.
Figure 1 is a calculated powder X-ray diffraction pattern of azithromycin form A. The scale of the abscissa is degrees 2-theta (2 6). The ordinate is the intensity in counts.
Figure 2 is an experimental powder X-ray diffraction pattern of azithromycin form A. The scale of the abscissa is in degrees 2-theta (2 8). The ordinate is the intensity in counts.
Figure 3 is an overlay of Figures 1 and 2 with the calculated diffraction patterns of "azithromycin form A (Figure 1) on the bottom and the experimental diffraction pattern of azithromycin form A (Figure 2) on the top. The scale of the abscissa is in degrees 2-theta (2 6).
The ordinate is the intensity in counts,
Figure 4 is a calculated powder X-ray diffraction pattern of azithromycin form C. The scale of the abscissa is in degrees 2-theta (2 8). The ordinate is the intensity in counts.
Figure 5 is a calculated powder X-ray diffraction pattern of azithromycin form D. The scale of the abscissa is in degrees 2-theta (2 8). The ordinate is the intensity in counts.
Figure 6 is an experimental powder X-ray diffraction pattern of azithromycin form D. ’
The scale of the abscissa is in degrees 2-theta (2 98). The ordinate is the intensity in counts.
Figure 7 is an overlay of Figures 5 and 6 with the calculated diffraction pattem of azithromycin form D (Figure 5) on the bottom and the experimental diffraction pattern of azithromycin form D (Figure 6) on the top. The scale of the abscissa is in degrees 2-theta (2 6).
The ordinate is the intensity in counts.
Figure 8 is a calculated powder X-ray diffraction pattern of azithromycin form E. The scale of the abscissa is in degrees 2-theta (2 8). The ordinate is the intensity in counts.
Figure 9 is a calculated powder X-ray diffraction pattern of azithromycin form F. The scale of the abscissa is in degrees 2-theta (2 6). The ordinate is the intensity in counts.
Figure 10 is an experimental powder X-ray diffraction pattern of azithromycin form F.
The scale of the abscissa is in degrees 2-theta (2 8). The ordinate is the intensity in counts.
Figure 11 is an overlay of Figures 9 and 10 with the calculated diffraction pattern of azithromycin form F (Figure 9) on the bottom and the experimental diffraction pattern of azithromycin form F (Figure 10) on the top. The scale of the abscissa is in degrees 2-theta (2 0).
The ordinate is the intensity in counts.
Figure 12 is a calculated powder X-ray diffraction pattern of azithromycin form G. The scale of the abscissa is in degrees 2-theta (2 8). The ordinate is the intensity is counts.
Figure 13 is an experimental powder X-ray diffraction pattern of azithromycin form G.
The scale of the abscissa is in degrees 2-theta (2 6). The ordinate is the intensity in counts. :
Figure 14 is an overlay of Figures 12 and 13 with the calculated diffraction pattern of azithromycin form G (Figure 12) on the bottom and the experimental diffraction pattern of azithromycin form G (Figure 13) on the top. The scale of the abscissa is in degrees 2-theta (2 8). The ordinate is the intensity in counts.
Figure 15 is a calculated powder X-ray diffraction pattern of azithromycin form J. The scale of the abscissa is in degrees 2-theta (2 8). The ordinate is the intensity in counts.
Figure 16 is an experimental powder X-ray diffraction pattern of azithromycin form J.
The scale of the abscissa is in degrees 2-theta (2 8). The ordinate is the intensity in counts.
Figure 17 is an overlay of Figures 15 and 16 with the calculated diffraction pattern of azithromycin form J (Figure 15) on the bottom and the experimental diffraction pattern of azithromycin form J (Figure 16) on the top. The scale of the abscissa is in degrees 2-theta (2 9).
The ordinate is the intensity in counts.
Figure 18 is an experimental powder X-ray diffraction pattern of azithromycin form M.
The scale of the abscissa is in degrees 2-theta (2 0). The ordinate is the intensity in counts.
Figure 19 is an experimental powder X-ray diffraction pattern of azithromycin form N.
The scale of the abscissa is in degrees 2-theta (2 6). The ordinate is the intensity in counts.
-g-
Figure 20 is an experimental powder X-ray diffraction pattern of amorphous azithromycin. The scale of the abscissa is in degrees 2-theta (2 8). The ordinate is the intensity in counts.
Figure 21 is a 3C solid state NMR spectrum of azithromycin form A.
Figure 22 is a "°C solid state NMR spectrum of azithromycin form D.
Figure 23 is a "°C solid state NMR spectrum of azithromycin form F.
Figure 24 is a "°C solid state NMR spectrum of azithromycin form G.
Figure 25 is a *>C solid state NMR spectrum of azithromycin form J.
Figure 26 is a 3¢ solid state NMR spectrum of azithromycin form M.
Figure 27 is a ">C solid state NMR spectrum of azithromycin form N.
Figure 28 is a "°C solid state NMR spectrum of amorphous azithromycin.
Figure 29 is a 3C solid state NMR spectrum of a pharmaceutical tablet containing form
G azithromycin.
Figure 30 is an experimental powder X-ray diffraction pattern of azithromycin form Q.
The scale of the abscissa is in degrees 2-theta (2 0). The ordinate is the intensity in counts.
Figure 31 is an experimental powder X-ray diffraction pattern of azithromycin form R.
The scale of the abscissa is in degrees 2-theta (2 ©). The ordinate is the intensity in counts.
Figure 32is a 3C solid state NMR spectrum of azithromycin form H.
Figure 33 is a "°C solid state NMR spectrum of azithromycin form R.
Azithromycin has been found to exist in different crystalline forms. A dihydrate, form
A, and a non-stroichiometric hydrate, form B, are disclosed in European Patent EP 298 650 and U.S. Patent 4,512,359, respectively. Sixteen other forms have been discovered, namely fooms C,D,E,F,G, H, I,J, K, L, M,N, O, P, Q and R. These forms are either hydrates or hydrate/solvates of azithromycin free base. Forms L and K are the metastable lower hydrate forms of A, detected at high temperature. Crystal structures of forms A, C,D,E, F, G, H, J and O have been solved. The structural data of these crystal forms are given below:
Table 1: Crystallographic data of azithromycin form A. - FomA “Empirical formula CypHpN;0,2,0
Formula weight 785.2
Crystal size (mm) 0.19 x 0.24 x 0.36
Space group P2,2,2, orthorhombic
Unit cell dimensions a=14.735(5) A . b=16.844 (7) A c=1781 (HA a= 90°
B= 90° y= 90°
Z (per formula) 4
Density (g/cm?) 1.18
R 0.060
Table 2: Crystallographic data of azithromycin form C. ~~ FomCc “Empirical formula CysHpN2OpH;O
Formula weight 767.15
Crystal size (mm) 0.16x0.16x 0.19
Space group P2,2,2, orthorhombic
Unit cell dimensions a=28.809(3)A b=12.4750 (8) A c=4559 (3) A a= 90°
B=90° y=90°
Z (per formula) 4
Density (g/cm) 1.01
R 0.106
Table 3: Crystallographic data of azithromycin form D. - _FomD “Empirical formula CasHnoNoO12*H,0°Cellz
Formula weight 851.15
Crystal size (mm) 0.52x0.32x0.16
Space group P2,2,2, orthorhombic
Unit cell dimensions a= 28.8710 (10) A b=12.506 (2) A c=45.697 (7) A a= 90° p= 90° y=90°
Z {per formula) 4
Density (g/lcm®) 1.12
R 0.0663
Table 4: Crystallographic data of azithromycin form E. ~~ Fome “Empirical formula CygHpN:Op'H;0-CHO
Formula weight 839.2
Crystal size (mm) 0.17x 0.19 x 0.20
Space group P2,2,2, orthorhombic
Unit cell dimensions a=28.869 (3) A . b=12.086(3) A ¢=46.00 (1) A a= 90° p= 90° y=90°
Z (per formula) 4
Density (g/cm) 1.13
R 0.087 :
Table 5: Crystallographic data of azithromycin form F. fmf “Empirical formula CagHpN.Op'H20°0.5GHO
Crystal size (mm) 0.14x0.20x 0.24
Formula weight 790.2
Space group P2, monoclinic
Unit cell dimensions a= 16.281 (2) A b=16.293(1) A c=18.490 (3) A a= 90° p=109.33(1)° y=90°
Z (per formula) 4
Density (g/cm?) 1.13
R 0.0688
Table 6: Crystallographic data of azithromycin form G. . : ~~ FomG “Formula CuHpNOpeISHO
Formula weight 776.0
Crystal size (mm) 0.04 x 0.20 x 0.24
Space group P2, monoclinic
Unit cell dimensions a= 16.4069(8) A b=162922(8) A c= 18.3830 (9) A o= 90°
B=110.212(2)° y= 90°
Z (per formula) 4
Density (glem®) 1.12
R 0.0785 :
Table 7: Crystallographic data of azithromycin form H. -— — Fomn “Empirical formula CygHpN;0,-ILO05CH:0,
Crystal size (mm) 0.14x0.20x 0.24
Formula weight 805.0
Space group P2, monoclinic
Unit cell dimensions a=16.177(H A b=16.241(2)A c=18.614(A a= 90°
B= 108.34 (1)° y =90°
Z (per formula) 4
Density (g/cm®) 1.15
R 0.0687
Table 8: Crystallographic data of azithromycin form J. - _——"¥fomJ “Formula GuHnNoOpH,0-05GHO
Formula weight | 796.0
Crystal size (mm) 0.40x0.36x0.20
Space group P2, monoclinic
Unit cell dimensions a=16.191(6) A b =16.237(10) A c= 18.595(14) A o=90°
B= 108.92(4)° y=90°
Z (per formula) 4
Density (g/cm®) 1.14
R 0.0789
Table 8A: Crystallographic data of azithromycin form O. -— FfFomo “Formula CagHnN:0;p°0.5H,0 0.5C;H 0
Formula weight 795.04
Crystal size (mm) 0.40% 0.36% 0.20
Space group P2, monoclinic
Unit cell dimensions a=16.3602(11) A b=16.2042(11) A c=18.5459(12) A o=90°
B= 109.66(10)° y=90° .
Z (per formula) 4
Density (g/cm) 1.14
R 0.0421
Among these sixteen crystal forms, two isomorphic families are identified. Family | : includes forms F, G, H, J, M, N, O, and P. Family ll includes forms C, D, E and R. Form Q is distinct from families | and Il. The forms within a family are isomorphs that crystallize in the same space group with slight variation of cell parameters and comprise chemically related structures but different elemental composition. In this case, the variation in chemical composition among the isomorphs arises from incorporation of different water/solvent molecules. Consequently, the isomorphs display similar but non-identical X-ray diffraction patterns and solid-state NMR spectra (ssNMR). Other techniques such as near infrared spectroscopy (NIR), differential scanning calorimetry (DSC), gas chromatography (GC), thermalgravimetric analysis (TGA), or thermalgravimetric analysis/infrared spectroscopy analysis (TG-IR), Karl Fischer water analysis (KF) and molecular modeling/visualization provide data for affirmative identification of isomorphs. Dehydration/desolvation temperatures were determined by DSC with a heating rate of 5°C/min
Form C: This crystal form was identified from a single crystal structure (Table 2) - a monohydrate of azithromycin. It has the space group of P2,2,24 and similar cell parameters as that of forms D and E; therefore, it belongs to Family Il isomorphs. Its calculated powder pattern is similar to that of forms D and E.
Form D: Form D was crystallized from cyclohexane. The single crystal structure of form D shows a stoichiometry of a monohydrate/monocyclohexane solvate of azithromycin (Table 3). Cyclohexane molecules were found to be disordered in the crystal lattice. From single crystal data, the calculated water and cyclohexane content of form D is 2.1 and 9.9%, respectively. Both the powder pattern and the calculated powder pattern of form D are similar to those of forms C and E. The powder samples of form D showed a desolvation/dehydration endotherm with an onset temperature of about 87°C and a broad endotherm between 200- 280°C (decomposition) in DSC analysis at 5°C/min from 30-300°C.
Form D is prepared by slurrying azithromycin in cyclohexane for 2-4 days. The solid form D azithromycin is collected by filtration and dried.
Form E: Form E was obtained as a single crystal collected in a THF /water medium. it is a monohydrate and mono-THF solvate by single crystal analysis (Table 4). By its single crystal structure, the calculated PXRD pattern is similar to that of form C and form D making it a family # isomorph.
Form E is prepared by dissolving azithromycin in THF (tetrahydrofuran). Diffusing water vapor to saturated azithromycin THF solution over time yields crystals of Form E.’
Form F: The single crystal of form F crystallized in a monoclinic space group, P21, with the asymmetric unit containing two azithromycin, two waters, and one ethanol, as 2 monohydrate/hemi-ethanolate (Table 5). It is isomorphic to forms all family | azithromycin crystalline forms. The calculated PXRD pattern of this form is similar to those of other family isomorphs. The theoretical water and ethanol contents are 2.3 and 2.9%, respectively. The powder samples show a dehydration/desolvation endotherm at an onset temperature between 110-125°C. Form F is prepared by dissolving azithromycin in ethanol (1-3 volumes by weight) at a temperature of about 50-70°C. Upon complete dissolution, the solution is cooled to subambient temperature to cause precipitation. The volume of ethanol can be reduced by vacuum distillation with stirring for 1-2 hours to increase the yield. Alternatively, water (optionally chilled to 0-20°C) about 0.1-2 volume can be added with collection of solids within 30 minute after water addition. Cooling the ethanol solution of azithromycin prior to the addition of water to below below 20°C, preferably betow 15°C, more preferably below 10, and most preferably 5°C results in substantially pure azithromycin form F. The solid form F azithromycin is collected by filtration and dried.
Form G: The single crystal structure of form G consists of two azithromycin molecules and three water molecules per asymmetric unit (Table 6). This corresponds to a : sesquihydrate with a theoretical water content of 3.5%. The water content of powder samples of form G ranges from about 2.5 to about 6%. The total residual organic solvent is less than 1% of the corresponding solvent used for crystallization, which is well below stoichiometric quantities of solvate. This form dehydrates with an onset temperature of about 110 -120°C.
Form G may be prepared by adding azithromycin to a premixed organic solvent/water mixture (1/1 by volume), where the organic solvent can be methanol, acetone, acetonitrile, ethanol or isopropanol. The mixture is stirred and heated to an elevated temperature, e.g. 45- 55°C for 4-6 hours to cause dissolution. Precipitation occurs during cooling to ambient temperature. The solid form G azithromycin is collected by filtration and dried.
Form H: This crystal form is a monohydrate/hemi-propylene glycol solvate of azithromycin free base (Table 7). It was isolated from a formulation solution containing propylene glycol. The crystal structure of form H is isomorphic to crystal forms of Family |.
Azithromycin form H is prepared by dissolving azithromycin dihydrate in 6 volumes of propylene glycol. To the resulting propylene glycol solution of azithromycin, 2 volumes of water is added and precipitation occurrs. The slurry is stirred for 24 hours and the solids are filtered and air-dried at ambient temperature to afford crystalline Form H.
Form J: Form J is a monohydrate/hemi n-propanol solvate (Table 8). The calculated solvent content is about 3.8% n-propanol and about 2.3% water. The experimental data shows from about 2.5 to about 4.0% n-propancl and from about 2.5 to about 3% water content for powder samples. Its PXRD pattern is very similar to those of its isomorphs F, G,
H, Mand N. Like F and G, the powder samples have a dehydration/desolvation endotherm at 115 - 125°C.
Form J is prepared by dissolving azithromycin in 4 volumes of n-propanol at a temperature of about 25-55°C. Water, about 6-7 volumes, is added at room temperature and
S the slurry is continuously stirred for 0.5-2 hours. The solid form J azithromycin is collected by filtration and dried.
Form K: The PXRD pattern of form K was found in a mixture of azithromycin form A and microcrystalline wax after annealing at 95°C for 3 hours. It is a lower hydrate of form A and is a metastable high temperature form.
Form L: This form has only been observed upon heating the dihydrate; form A. In variable temperature powder X-ray diffraction (VT-PXRD) experiments, a new powder X-ray diffraction pattern appears when form A is heated to about 90°C. The new form, designated form L, is a lower hydrate of form A because form A loses about 2.5 weight % at 90 °C by
TGA, thus corresponding to a conversion to a monohydrate. When cooled to ambient temperature, form L rapidly reverts to form A.
Form M: Isolated from an isopropanol/water slurry, form M incorporates both water and isopropanol. Its PXRD pattern and ss-NMR spectrum are very similar to those of Family isomorphs, indicating that it belongs to Family I. By analogy to the known crystal structures of
Family 1 isomorphs, the single crystal structure of form M would be a monohydrate/hemi- isopropranolate. The dehydration/desolvation temperature of form M is about 115-125°C.
Form M may be prepared by dissolving azithromycin in 2-3 volumes of isopropanol (IPA) at 40-50°C. The solution is cooled to below 15°C, preferably below 10°C, more preferably about 5°C and 2-4 volumes of cold water about 5°C are added to effect precipitation. Seeds of form M crystals may be added at the onset of crystallization. The slurry is stirred less than about 5 hours, preferably less than about 3 hours, more preferably less than about 1 hour and most preferably about 30 minutes or less and the solids are collected by filtration. The solids may be reslurried in isopropanol. This procedure provides form M substantially in the absence of azithromycin dihydrate.
Form N: Isolated from water/ethanol/isopropanol slurry of form A, form N crystals may contain variable amounts of the crystallization solvents and water. Its water content varies from about 3.4 to about 5.3 weight percent. Analysis by GC Headspace reveals a variable solvent content of ethanol and isopropanol. The total solvent content of form N samples is usually lower than about 5% depending on the conditions of preparation and drying. The PXRD pattern of form N is similar to that of forms F, G, H, J and M of the Family isomorphs. The dehydration/desolvation endotherm(s) of the samples of form N may be broader and may vary between 110-130°C.
Form N azithromycin may be prepared by recrystallizing azithromycin from a mixture of azithromycin crystal latice-incorporating organic solvents and water, such as ethanol, isopropanol, n-propanol, acetone, acetonitirile etc. The solvent mixture is heated to 45-60°C and azithromycin is added to the heated solvent mixture, up to a total of about 4 volumes.
Upon dissolution, 1-3 volumes of water are added with continuous agitation at 45-60°C. Form
N azithromycin precipitates as a white solid. The slurry is allowed to cool to ambient temperature with stirring. Solid form N azithromycin is isolated by filtration and dried.
Form O: This crystal form is a hemihydrate hemi-n-butanol solvate of azithromycin free base by single crystal structural data (Table 8A). It was isolated from n-butanol solution of azithromycin with diffusion of antisolvent. The crystal structure of form O is isomorphic to crystal forms of Family 1.
Azithromycin is completely dissolved in n-butanol. Addition of an antisolvent, such as hexane, water, IPE or other non-solvent, by diffusion results in precipitation of Form O.
Form P: This is a proposed crystal form, being a hemihydrate hemi-n-pentanol solvate of azithromycin free base. It can be isolated from an n-pentanol solution of azithromycin with diffusion of an antisolvent. The crystal structure of form P is isomorphic to crystal forms of Family I.
Form P of azithromycin may be prepared as following: Azithromycin is completely dissolved in n-pentanol; addition of an antisolvent, such as hexane, water, isopropyl ether (IPE) or other non-solvent, by diffusion results in precipitation of Form P.
Form Q: The crystal form of Q exhibits a unique powder X-ray diffraction pattern. It contains about 4% water and about 4.5% THF, being a hydrate hemi THF solvate. The main dehydration/desolvation temperature is from about 80 to about 110°C.
Azithromycin dihydrate is dissolved in 6 volumes of THF and 2 volumes of water are - added. The solution is allowed to evaporate to dryness at ambient conditions to afford crystalline Form Q.
Form R: This crystalline form is prepared by adding amorphous azithromycin to 2.5 volumes of tert-butyl methyl ether (MTBE). The resuiting thick white suspension is stirred 3 days at ambient conditions. Solids are collected by vacuum filtration and air dried. The resulting bulk azithromycin form R has a theoretical water content of 2.1 weight % and a theoretical methyl tert-butyl ether content of 10.3 weight %.
Due to the similarity in their structures, isomorphs have propensity to form a mixture of the forms within a family, sometimes termed as ‘mixed crystals’ or ‘crystalline solid solution’. Form Nis such a solid crystalline solution and was found to be a mixture of Family isomorphs by solvent composition and solid-state NMR data.
Both Family | and Family II isomorphs are hydrates and/or solvates of azithromycin.
The solvent molecules in the cavities have tendency to exchange between solvent and water under specific conditions. Therefore, the solvent/water content of the isomorphs may vary to a certain extent.
The crystal forms of isomorphic Family | are more stable than form A when subjected to heating. Forms F, G, H, J, M and N showed higher onset dehydration temperatures at 110- 125°C than that of form A with an onset dehydration temperature at about 90 to about 110°C and simultaneous solid-state conversion to form L at about 90°C.
Amorphous azithromycin: All crystal forms of azithromycin contain water or solvent(s) or both water and solvent(s). When water and solvent(s) are removed from the crystalline solids, azithromycin becomes amorphous. Amorphous solids have advantages of high initial dissolution rates.
The starting material for the synthesis of the various crystal forms in the examples below was azithromycin dihydrate unless otherwise noted. Other forms of azithromycin such as amorphous azithromycin or other non-dihydrate crystalline forms of azithromycin may be used.
Example 1: Preparation of Form D
Form D was prepared by slurrying azithromycin dihydrate in cyclohexane for 2-4 days at an elevated temperature, e.g. 25-50°C. The crystalline solids of form D were collected by filtration and dried.
Example 2: Preparation of Form F 2A: Azithromycin dihydrate was slowly added to one volume of warm ethanol, about 70°C, and stirred to complete dissolution at 65 to 70°C. Seeds of Form F 1- 2% wt may be introduced to facilitate the crystallization. The solution was allowed to cool gradually to 2 — 5°C and one volume of chilled water was added The crystalline solids were collected shortly (preferably less than 30 minutes) after addition of water by vacuum filtration. 2B: Azithromycin dihydrate is slowly added to one volume of warm ethanol, about 70°C, and stirred to complete dissolution at 65 to 70°C. Seeds of Form F 1- 2% wt may be introduced to facilitate the crystallization. The solution is allowed to cool gradually to 2 — 5°C and ethanol volume may be reduced by vacuum distillation. After stirring up to 2 hours the crystalline solids are collected by vacuum filtration. The isolation of the crystals yields substantially pure form F azithromycin, form F azithromycin substantially free of form G azithromycin and form F azithromycin substantially free of azithromycin dihydrate.
-19- Co
Example 3: Preparation of Form G
A reaction vessel was charged with form A azithromycin. In a separate vessel, 1.5 volumes methanol and 1.5 volumes water were mixed. The solvent mixture was added to the reaction vessel containing the form A azithromycin. The slurry was stirred with heating to 50°C for approximately 5 hours. Heating was discontinued and the slurry was allowed to cool with stirring to ambient temperature. The form G azithromycin was collected by filtration and allowed to air dry for approximately 30 minutes. The collected form G azithromycin was further dried in a vacuum oven at 45°C. This procedure yields substantially pure form G azithromycin, and form G azithromycin substantially free of azithromycin dihydrate.
Example 4: Preparation of Form J
Form J was prepared by dissolving azithromycin in 4 volumes of n-propanol at a temperature of about 25°C. Water (6.7 volumes) was added and the slurry is continuously stirred for 1 hour, followed by cooling to about 0°C. The solid form J azithromycin was collected by filtration and dried.
Example 5: Preparation of Form M Substantially in the Absence of Azithromycin
Dihydrate 5A: Azithromycin dihydrate is completely dissolved in 2 volumes of warm isopropanol 40 —- 50°C. Seeds of Form M may be optionally introduced to facilitate the crystallization. The solution is then cooled to 0-5°C and 4 volumes of chilled water as antisolvent are added and the solids are collected by vacuum filtration. The solids are reslurried in 1 volume of isopropanol for 3-5 hours at 40-45 °C and then cooled to 0-5°C. The crystalline solids are collected shortly (about 15 minutes) after addition of water by vacuum filtration. The solids are reslurried in 0.5 to 1 volume of isopropanol at 25-40°C and cooled to about 5°C followed by filtration to collect solids of form M. 5B: Azithromycin dihydrate (1940 grams) was completely dissolved in 2 volumes of warm isopropanol (45°C). The resulting clear solution was filtered through an inline 0.2 pm filter into a clean flask. The temperature was maintained at 45°C and the solution was seeded with form M crystals. 7.8 L of chilled water was added over 8 minutes. The solution was cooled to 5°C and a thick slurry was noted. The solids were isolated by vacuum filtration and transferred to a clean flask. The crystalline azithromycin was slurried in 1 volume of isopropanol alcohol with warming to 35°C. The slurry was then cooled to 5°C for 30 minutes and the solid crystalline material was filtered off.
These procedures yield substantially pure form M azithromycin, form M azithromycin substantially free of form G azithromycin and form M azithromycin substantially free of azithromycin dihydrate
Example 6: Preparation of Form N
Two volumes of ethanol and 2 volumes of isopropanol were added to a reaction vessel and heated to 50°C. Azithromycin form A was added with stirring to the heated ethanol/isopropanol mixture to yield a clear solution. The reaction vessel was charged with 2 volumes distilled water (ambient temperature). Stirring was continued at 50°C and solid form N azithromycin precipitated after approximately 1 hr. Heating was discontinued 5 hours after the addition of the water. The slurry was allowed to cool to ambient temperature.
Precipitated form N azithromycin was collected by filtration and dried for 4 hours in vacuum oven at 45°C.
Example 7: Preparation of amorphous azithromycin
Crystalline form A azithromycin was heated to 110-120°C in an oven for overnight under vacuum. The amorphous solids were collected and stored with desiccant as needed.
Example 8: Preparation of Form H
Azithromycin dihydrate or other crystal forms was dissolved in 6 volumes of propylene glycol. To the resulting propylene glycol solution of azithromycin, 2 volumes of water were added and precipitation occurred. The slurry was stirred for 24 hours and the solids were filtered and air-dried at ambient temperature to afford crystalline Form H.
Example 9: Preparation of Form Q
The crystaliine powder was prepared by dissolving 500 mg azithromycin Form Ain 2 ml THF. To the clear, colorless solution at room temperature was added 1 ml water. When the solution became cloudy an additional Tmt THF was added to dissolve the azithromycin completely, and the solution was stirred at ambient temperature. Solvent was allowed to evaporate over 7 days, after which the dry solids were collected and characterized.
Example 10: Powder X-ray diffraction analysis
Powder patterns were collected using a Bruker D5000 diffractometer (Madison,
Wisconsin) equipped with copper radiation, fixed slits (1.0, 1.0, 0.6mm), and a Kevex solid state detector. Data was collected from 3.0 to 40.0 degrees in 2 theta using a step size of 0.04 degrees and a step time of 1.0 seconds. The results are summarized in Table 9.
The experimental PXRD diffraction paitern of azithromycin form A is given in figure 2.
The experimental PXRD diffraction pattern of azithromycin form D is given in figure 6.
The experimental PXRD diffraction pattern of azithromycin form F is given in figure 10.
The experimental PXRD diffraction pattern of azithromycin form G is given in figure 13.
The experimental PXRD diffraction pattern of azithromycin form J is given in figure 16.
The experimental PXRD diffraction pattern of azithromycin form M is given in figure
The experimental PXRD diffraction pattern of azithromycin form N is given in figure
The experimental PXRD diffraction pattern of amorphous azithromycin is given in figure 20.
The experimental PXRD diffraction pattern of azithromycin form Q is given in figure 30. :
The experimental PXRD diffraction pattern of azithromycin form R is given in figure 31.
The experimental variability from sample to sample is about + 0.2° in 2 theta, and the same variations were observed between the calculated powder from single crystal structure and experimental data. Detailed analysis showed that the isomorphs in Family | can be discerned by PXRD with sets of characteristic peaks given in Table 9. 5 Table 9. Azithromycin Powder X-ray Diffraction Peaks in 2-theta +0.2° 7.2 3.9 5.7 5.0 5.0 6.2 57 es
CT CX 2 CE CI OT pre | jm me jms es PR [08
CE A CCR NN
I EN CR CC CS fee me Jee pe J PF
I CC CEA I a
I I CC CC CC I
I CR CS I
IE CI CR CCN CR
I A CEA CE CA RE
I EE CCR
Es nn Bs Rc —
IE CN EN NR I RE
GN HN JS WE
The peaks underlined are the characteristic peaks among forms A, D, Family | and Q.
The peaks in italic and underlined are the sets of peaks that are characteristic within Family isomorphs.
Family | isomorphs have the following common characteristics: the diffraction peaks at 6.2, 11.2, 21.0£0.1 and 22.5 +0.1 degree in 2-theta. Each isomorph displays representative sets of diffraction peaks given in the following, and each set has characteristic ) spacing between the peaks.
The diffraction peak positions reported are accurate to within + 0.2 degree of 2-theta.
A representative PXRD pattern of form A is shown in figure 2. Form A displays peaks at 9.3, 13.0 and 18.7 degrees of 2-theta.
A representative PXRD pattern of form D is shown in figure 6. Form D displays peaks at 3.9, 10.1, 10.6 and 21.4 degrees of 2-theta.
A representative PXRD pattern of Form F is shown in figure 10. Form F displays the characteristic peaks of Family | and three sets of peaks, being set 1 at 2-theta of 11.2 and 11.5; set 2 at 2-theta of 13.9, 14.3, 14.7 and 14.8; set 3 at 2-theta of 16.2, 16.6, 17.1, 17.2 and 17.7.
A representative PXRD pattern of Form G is shown in figure 13. Form G displays the characteristic peaks of Family | and three sets of peaks, being set 1 at 2-theta of 11.2 and
11.6 2; set at 2-theta of 14.0, 14.4, 14.6 and 14.9; set 3 at 2-theta of 16.3, 16.6, 17.2, 17.4 and 17.8.
A representative PXRD pattern of Form J is shown in figure 16. Form J displays the characteristic peaks of Family | and three sets of peaks, being set 1 at 2-theta of 11.2 and 11.4; set 2 at 2-theta of 13.9, 14.2 and 14.6; set 3 at 2-theta of 16.0, 16.6, 17.0, 17.2 and 17.5.
A representative PXRD pattern of Form M is shown in figure 18. Form M displays the characteristic peaks of Family | and three sets of peaks, being set 1 at 2-theta of 11.2; set 2 at 2-theta of 14.0 and 14.6; set 3 at 2-theta of 15.9, 16.6, 17.1 and 17.5.
A representative PXRD pattern of Form N is shown in figure 10. Form N displays the characteristic peaks of Family I. The sets of peaks of form N are similar to those of forms F,
G, J and M, being set 1 at 2-theta of 11.2 to 11.6; set 2 at 2-theta of 13.9 to 15.0; and set 3 at 2-theta of 15.9 to 17.9, with the peaks may vary slightly in position, intensity and width due to mixing of variable proportion of isomorphs in Family |.
A representative PXRD pattern of form Q is shown in figure 30. Form Q displays peaks at 2-theta of 6.8, 8.4 and 20.2 degree.
A representative PXRD pattern of form R is shown in figure 31.
Example 11: Single crystal X-ray analysis
Data were collected at room temperature using Bruker X-ray diffractometers equipped with copper radiation and graphite monochromators. Structures were solved using direct methods. The SHELXTL computer library provided by Bruker AXS, Inc facilitated all necessary crystallographic computations and molecular displays (SHELXTL™ Reference
Manual, Version 5.1, Bruker AXS, Madison, Wisconsin, USA (1997)).
Example 12: Calculation of PXRD pattern from single crystal data
To compare the results between a single crystal and a powder sample, a calculated powder pattern can be obtained from single crystal results. The XFOG and XPOW computer programs provided as part of the SHELXTL computer library were used to perform this calculation. Comparing the calculated powder pattern with the experimental powder pattern confirms whether a powder sample corresponds to an assigned single crystal structure (Table 9A). This procedure was performed on the crystal forms of azithromycin A, D, F, G, and J.
The calculated PXRD diffraction pattern of azithromycin form A is given in figure 1.
The calculated PXRD diffraction pattern of azithromycin form D is given in figure 5.
The calculated PXRD diffraction pattern of azithromycin form F is given in figure 9.
The calculated PXRD diffraction pattern of azithromycin form G is given in figure 12.
The calculated PXRD diffraction pattern of azithromycin form J is given in figure 15.
The results are displayed in the overlaid powder X-ray diffraction patterns for forms A,
D, F, G, and J in figures 3, 7, 11, 14 and 17, respectively. The lower pattern corresponds to the calculated powder pattern (from single crystal results) and the upper pattern corresponds to a representative experimental powder pattern. A match between the two patterns indicated the agreement between powder sample and the corresponding single crystal structure.
Table 9A: Cacluated and Experimental PXRD Peaks of Isomorphs of Family calculated experimental calculated experimental [Mexpernimenta
I 50 1 57 58 538 57 | 56 6.3 6.2 62 6.2 63 6.2 2 74 75 74 74 73 7.3 70 78 Ke] 79 7.9 7.8 78 ~— 88 89 89 93 8.3 82 82 } 99 938 9.9 99 98 a7 98 0.3 10.3 70.2 104 103 10.2 10.9 106° 0.8 113 1122 113 11.2 1.2 112 12 11.5 14 “116 16 11.4 114 missing 12.0 179 120 11.9 12.0 — 719 11.9 123 122 123 123 TTT23 T1220 126 i25 | 125 125 25 14.0 “40 TTA34 133 14.0 13.9 14.0 43 43 Tia 32 Taz missing — 144 44 14.7 47 47 136 | 47 146 | 148 14.9 14.8 149 149 148 wr 15.4 15.3 15.4 3 | 153 153 15.3 15.8 157 15.7 157 158 157 15.9 ~~ 16.2 6.2 6.3 16.3 16.0 16.0 missing 16.6 16.6” 16.6 66 8.7 16.6 16.6
BIA 7.2" 171 — — Al 7.0 71 17.3 173 73 17.2 174° 172 missing”
TTs 74 75 747 786 75
BIA 17.7 79 178 179 — 5 180 80 18.7 1871 182 18.7 184 18.6 185 18.7 87 85 185 85 “19.4 19.0 19.1 9.0 19 90 19.1 . 97 196 96 196 70.8 19.7 19.6 20.0 20.0 20.0 20.0 201 200 200 20.5 204 206 205 205 204 204° 21.1 270 21.2 21.0 20.8 209 209 218 217 216 216 217 A7 221 22.0 218 2138 21.8 225 224 22. 2 22. 224 285 227 226 WE 238 276 231 231 29 | | 234 | 233 I 238 235 235 235 237 235 236
Example 13: Solid State NMR Analysis
Solid State NMR analysis:
All °C solid state NMR spectra were collected on an 11.75 T spectrometer (Bruker ~ Biospin, Inc., Billerica, MA), corresponding to 125 MHz °C frequency. The spectra were collected using a cross-polarization magic angle spinning (CPMAS) probe operating at ambient temperature and pressure. Depending on the quantity of sample analyzed, 7 mm BL or 4 mm BL Bruker probes were employed, accomodating 300 mg and 75 mg of sample with maximum speeds of 7 kHz and 15 kHz, respectively. Data were processed with an exponential line broadening function of 5.0 Hz. Proton decoupling of 65 kHz and 100 kHz were used with the 7mm and 4 mm probes, respectively. A sufficient number of acquisitions were averaged out to obtain adequate signal-to-noise ratios for all peaks. Typically, 600 scans were acquired with recycle delay of 3.0 s, corresponding approximately to a 30 minute total acquisition time. Magic angle was adjusted using KBr powder according to standard
NMR vendor practices. The spectra were referenced relative to either the methyl resonace of hexamethylbenzen (HMB) at 17.3 ppm or the upfield resonance of adamantane (ADM) at 29.5 ppm. HMB referenced spectra show chemical shifts of all peaks shifted down field by 0.08 ppm with respect to same spectra referenced to ADM. The spectral window minimally included the spectra region from 190 to 0 ppm. The results are summarized in Table 10. Ss-
NMR spectra for forms M, H and R were referenced to ADM. Ss-NMR spectra for forms A, D,
GG, F, J and N were referenced to HMB. Forms H and R were spun at a rate of 15 kHz.
Table 10. °C ss-NMR chemical shifts of Azithromycin (+ 0.2 ppm)
AS NN JAN A J LIN AN NN
104.1 103.9 1055 178.6 orf 178.7 ~~ [104.6 84.6 B42 50 11034 103.4 as [1036 103.2 95.3 osprey eos pas 63.2 B47 por p91 6 9.2 67.3 po.7 [M2 po
17.5 16.7 37.5 37.3 PEST 336 P65 09 27.4 15.9 [i6.1 ors B54 p01 p37 37.1 214 13.2 10.6 3.6 0.4 6.3 20.8 13 po B00 p03 7.2 8.1 B37 ig 2 js 8.0 28.0 brs 16.5
The chemical shifts labeled in bold and underlined are the peaks or sets of peaks representative of each form. The chemical shifts labeled in italic are the solvent peaks that may be broad and variable (+ 0.4ppm). The chemical shifts labeled with single asterisk may show splitting of < 0.3 ppm. The chemical shifts labeled with double asterisks may show variation of £ 0.3 ppm
Table 10 (continued). °C ss-NMR chemical shifts of Azithromycin (+ 0.2 ppm) pv ps peg ms pep
AE EN 2 J a A er pe yes ez ps
IS IS A A a A
IE CN A LL
IE NY NN XS CN I LA
EE J —
IE FS I NS FR NN
EE PS I Ps Ss So
RE I I
The chemical shifts labeled in bold and underlined are the peaks or sets of peaks representative of each form. The chemical shifts labeled in italic are the solvent peaks that may be broad and variable (x 0.4ppm). The chemical shifts labeled with single asterisk may show splitting of < 0.3 ppm. The chemical shifts labeled with double asterisks may show variation of = 0.3 ppm
The chemical shifts reported are accurate to within £ 0.2 ppm unless otherwise indicated.
A representative °C ssNMR spectrum of form A is shown in figure 21. Form A displays a peak at 178.1 ppm, and peaks at 104.1, 98.4, 84.6, 26.9, 13.2, 11.3 and 7.2 ppm.
A representative 3¢ ssNMR spectrum of form D is shown in figure 22. Form D displays the highest chemical shift peak of 178.1 ppm and peaks at chemical shifts of 103.9, 95.1, 84.2, 10.6, 9.0 and 8.6 ppm.
A representative BC ssNMR spectrum of form F is shown in figure 23. Form F has two chemical shift peaks at approximately 179.1 + 2 ppm, being 179.5 ppm and 178.6 ppm,
and a set of 5 peaks at 10.1, 9.8, 9.3, 7.9, and 6.6 ppm, and ethanol peaks at 58.0+0.5 ppm and 17.2+0.5 ppm. The solvent peaks can be broad and relatively weak in intensity.
A representative '*C ssNMR spectrum of form G is shown in figure 24. Form G has the highest chemical shift peak of 179.5 ppm, being a single peak with possible splitting of < 0.3 ppm and a set of 5 peaks at 10.4, 9.9, 9.3, 7.6, 6.5 ppm.
A representative "°C ssNMR spectrum of form J is shown in figure 25. Form J has two chemical shift peaks at approximately 179.1 + 2 ppm, those being 179.6 ppm and 178.4 ppm, a set of 4 peaks at 10.0, 9.3, 8.1 and 6.8 ppm and n-propanol peaks at 11.5£0.5 ppm and 25.2:0.5 ppm. The solvent peak can be broad and relatively weak in intensity.
A representative "°C ssNMR spectrum of form M is shown in figure 26. Form M has one chemical shift peak at 179+1 ppm, being 179.6 ppm, peaks at 41.9, and 16.3 ppm, a set of 5 peaks at 10.3, 9.6, 9.3, 7.7 and 7.1 ppm and an isopropanol peak at 26.0+ 0.5 ppm. The solvent peak can be broad and relatively weak in intensity.
A representative °C ssNMR spectrum of form N is shown in figure 27. Form N displays chemical shifts as a combination of isomorphs in Family I. The peaks may vary in chemical shift and in relative intensities and width due to the mixing of variable proportion of isomorphs contained in the form N crystalline solid solution.
A representative BC ssNMR spectrum of amorphous form is shown in figure 28. The amorphous azithromycin displays broad chemical shifts. The characteristic chemical shifts have the peak positions at 179 and 11 + 0.5ppm.
A summary of the observed ssNMR peaks for forms A, D, F, G, H, J, M, N and R azithromycin is given in Table 10.
Example 14: NMR Analysis of a Dosage Form
To demonstrate the ability of °C ssNMR to identify the form of azithromycin contained in a pharmaceutical dosage form, coated azithromycin tablets containing form G azithromycin were prepared and analyzed by '*C ssNMR. Tablets were wet granulated and tabletted on an F-Press (Manesty, Liverpool, UK) using 0.262” x 0.531" tooling. Tablets were formulated and tabletted to contain 250 mg of form G azithromycin with a total tablet weight of 450 mg using the formula given below. The tablets were uniformly coated with pink Opadry
I® (mixture of lactose monohydrate, hydroxypropylmethylcellulose, titanium dioxide, Drug &
Cosmetic red # 30, and triacetin) (Colorcon, West Point, PA).
Material ~~ lPercentage i eC J
Anhydrous dicalcium phosphate
Soames aoe pov pw
Magnesium stearate with 10% sodium|2.92 8.76 laurel sulfate =
Total 10000 1300.00
A coated tablet was gently crushed and the powdered sample was packed with a packing tool in solid state rotor containing no °C background. Analysis of the sample was performed under conditions outlined in Example 13.
A representative ®C ssNMR spectrum of the tablet containing form G azithromycin is given in Figure 29.
Example 15: Antimicrobial activity:
The activity of the crystal forms of the present invention against bacterial and protozoa pathogens is demonstrated by the compound's ability to inhibit growth of defined strains of human (Assay I) or animal (Assays Hl and lil) pathogens.
Assay
Assay |, described below, employs conventional methodology and interpretation criteria and is designed to provide direction for chemical modifications that may lead to compounds that circumvent defined mechanisms of macrolide resistance. In Assay |, a panel of bacterial strains is assembled to include a variety of target pathogenic species, including representatives of macrolide resistance mechanisms that have been characterized. Use of this panel enables the chemical structure/activity relationship to be determined with respect to potency, spectrum of activity, and structural elements or modifications that may be necessary to obviate resistance mechanisms. Bacterial pathogens that comprise the screening panel are shown in the table below. In many cases, both the macrolide-susceptible parent strain and the macrolide-resistant strain derived from it are available to provide a more accurate assessment of the compound's ability to circumvent the resistance mechanism. Strains that contain the gene with the designation of ermA/ermB/ermC are resistant to macrolides, lincosamides, and streptogramin B antibiotics due to modifications (methylation) of 23S rRNA molecules by an Erm methylase, thereby generally prevent the binding of all three structural classes. Two types of macrolide efflux have been described; msrA encodes a component of an efflux system in staphylococci that prevents the entry of macrolides and streptogramins while mefA/E encodes a transmembrane protein that appears to efflux only macrolides.
Inactivation of macrolide antibiotics can occur and can be mediated by either a phosphorylation of the 2’-hydroxyl (mph) or by cleavage of the macrocyclic lactone (esterase).
The strains may be characterized using conventional polymerase chain reaction (PCR) technology and/or by sequencing the resistance determinant. The use of PCR technology in this application is described in J. Sutcliffe et al., “Detection Of Erythromycin-Resistant
Determinants By PCR", Antimicrobial Agents and Chemotherapy, 40(11), 2562-2566 (1996).
The assay is performed in microtiter trays and interpreted according to Performance
Standards for Antimicrobial Disk Susceptibility Tests - Sixth Edition, Approved Standard, published by The National Committee for Clinical Laboratory Standards (NCCLS) guidelines; the minimum inhibitory concentration (MIC) is used to compare strains. The crystalline compound is initially dissolved in dimethylsulfoxide (DMSO) as 40 mg/ml stock solution.
Assay Il is utilized to test for activity against Pasteurella multocida and Assay lif is utilized to test for activity against Pasteurella haemolytica.
Assay li
This assay is based on the liquid dilution method in microliter format. A single colony of :
P. multocida (strain 59A067) is inoculated into 5 ml of brain heart infusion (BHI) broth. The test compound is prepared by solubilizing 1 mg of the compound in 125 ul of dimethyisulfoxide (DMSO). Dilutions of the test compound are prepared using uninoculated BHI broth. The : concentrations of the test compound used range from 200 ug/ml to 0.098 pg/ml by two-fold serial dilutions. The P. multocida inoculated BHI is diluted with uninoculated BHI broth to make a 10* cell suspension per 200 pl. The BHI cell suspensions are mixed with respective serial dilutions of the test compound, and incubated at 37°C for 18 hours. The minimum inhibitory concentration (MIC) is equal to the concentration of the compound exhibiting 100% inhibition of growth of P. multocida as determined by comparison with an uninoculated control.
Assay li
This assay is based on the agar dilution method using a Steers Replicator. Two to five colonies isolated from an agar plate are inoculated into BHI broth and incubated overnight at 37°C with shaking (200 rpm). The next morning, 300 pl of the fully grown P. haemolytica preculture is inoculated into 3 ml of fresh BHI broth and is incubated at 37°C with shaking (200 rpm). The appropriate amounts of the test compounds are dissolved in ethanol and a series of two-fold serial dilutions are prepared. Two ml of the respective serial dilution is mixed with 18 ml of molten BHI agar and solidified. When the inoculated P. haernolytica culture reaches 0.5
McFarland standard density, about 5 nl of the P. haemolytica culture is inoculated onto BHI agar plates containing the various concentrations of the test compound using a Steers Replicator and incubated for 18 hours at 37°C. Initial concentrations of the test compound range from 100-200 ug/ml. The MIC is equal to the concentration of the test compound exhibiting 100% inhibition of growth of P. haemolytica as determined by comparison with an uninoculated control.
The in vivo activity of the crystal forms of the present invention can be determined by conventional animal protection studies well known to those skilled in the art, usually carried out in mice.
Mice are allotted to cages (10 per cage) upon their arrival, and allowed to acclimate for a minimum of 48 hours before being used. Animals are inoculated with 0.5 ml of a 3 x 10°
CFU/ml bacterial suspension (P. multocida strain 59A006) intraperitoneally. Each experiment has at least 3 non-medicated control groups including one infected with 0.1X challenge dose and two infected with 1X challenge dose; a 10X challenge data group may also be used.
Generally, all mice in a given study can be challenged within 30-90 minutes, especially if a repeating syringe (such as a Cornwall® syringe) is used to administer the challenge. Thirty minutes after challenging has begun, the first compound treatment is given. It may be necessary for a second person to begin compound dosing if all of the animals have not been challenged at the end of 30 minutes. The routes of administration are subcutaneous or oral doses. Subcutaneous doses are administered into the loose skin in the back of the neck whereas oral doses are given by means of a feeding needle. In both cases, a volume of 0.2 ml is used per mouse. Compounds are administered 30 minutes, 4 hours, and 24 hours after challenge. A control compound of known efficacy administered by the same route is included in each test. Animals are observed daily, and the number of survivors in each group is recorded.
The P. multocida model monitoring continues for 96 hours (four days) post challenge. ‘
The PDs, is a calculated dose at which the compound tested protects 50% of a group of mice from mortality due to the bacterial infection that would be lethal in the absence of drug treatment.
The crystal forms of the present invention (hereinafter “the active compound(s)”}, may be administered through oral, parenteral, topical, or rectal routes in the treatment or prevention of bacterial or protozoa infections. In general, the active compound is most desirably administered in dosages ranging from about 0.2 mg per kg body weight per day (mg/kg/day) to about 200 mg/kg/day in single or divided doses (i.e., from 1 to 4 doses per day), although variations will necessarily occur depending upon the species, weight and condition of the subject being treated and the particular route of administration chosen. However, a dosage level that is in the range of about 2 mg/kg/day to about 50 mg/kg/day is most desirably employed. Variations may nevertheless occur depending upon the species of mammal, fish or bird being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects, provided that such larger doses are first divided into several small doses for administration throughout the day.
The active compound may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by the routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, the active compound may be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, sachets, powders for oral suspension, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the active compound is present in such dosage forms at concentration levels ranging from about 1.0% to about 70% by weight.
For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active compound may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
For parenteral administration, solutions of the active compound in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques will known to those skilled in the art.
Additionally, it is also possible to administer the active compound topically and this may be done by way of creams, jellies, gels, pastes, patches, ointments and the like, in accordance with standard pharmaceutical practice.
For administration to animals other than humans, such as cattle or domestic animals, the active compounds may be administered in the feed of the animals or orally as a drench composition.
The active compound may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
Claims (15)
1. A crystalline form of azithromycin selected from the group consisting of forms D, E, substantially pure F, substantially pure G, H, J, M substantially in the absence of azithromycin dihydrate, N, O, P, Q, and R.
2. A crystalline form of azithromycin according to claim 1 wherein said form is form D and is further characterized as having a 13C solid state NMR spectrum having a peaks with chemical shifts of about 178.1 ppm, 103.9 ppm, 95.1 ppm, 84.2 ppm, 10.6 ppm, 9.0 ppm and 8.6 ppm.
3. A crystalline form of azithromycin according to claim 1 wherein said form is form E. 4, A crystalline form of azithromycin according to claim 1 wherein said form is substantially pure form F and is further characterized as having a 13C solid state NMR spectrum having a peaks with chemical shifts of about 179.5 ppm, 178.6 ppm,
58.0 ppm, 10.1 ppm 9.8 ppm, 9.3 ppm, 7.9 ppm and 6.6 ppm.
5. A crystalline form of azithromycin according to claim 4 wherein said azithromycin comprises 90% or more by weight of form F azithromycin.
6. A crystal form according to claim 1 wherein said form is substantially pure form G and is further characterized as having a 13C solid state NMR spectrum having a peaks with chemical shifts of about 179.5 ppm, 10.4 ppm, 9.9 ppm, 9.3 ppm, 7.6 ppm and
6.5 ppm.
7. A crystalline form of azithromycin according to claim 6 wherein said azithromycin comprises 90% or more by weight of form G azithromycin.
8. A crystal form according to claim 1 wherein said form is form H and is further characterized as having a 13C solid state NMR spectrum having a peaks with chemical shifts of about 179.5 ppm, 178.7 ppm, 9.9 ppm, 9.1 ppm, 7.9 ppm and 7.0 ppm.
9. A crystal form according to claim 1 wherein said form is form J and is further characterized as having a 13C solid state NMR spectrum having a peaks with chemical shifts of about 179.6 ppm, 178.4 ppm, 25.2 ppm, 11.5 ppm, 10.0 ppm, 9.3 ppm, 8.1 ppm and 6.8 ppm.
10. A crystal form according to claim 1 wherein said form is form M substantially in the absence of azithromycin dihydrate and is further characterized as having a 13C solid state NMR spectrum having a peaks with chemical shifts of about 179.6 ppm, 41.9 ppm, 26.0 ppm, 16.3 ppm, 10.3 ppm, 9.6 ppm, 9.3 ppm, 7.7 ppm and 7.1 ppm.
1. A crystal form according to claim 1 wherein said form is form N and is further characterized as having a 13C solid state NMR spectrum having a peaks with chemical shifts of about 179.6 ppm, 178.7 ppm, 105.6 ppm, 58.1 ppm, 26.0 ppm, 9.9 ppm, 9.4 ppm, 7.9 ppm, and 6.6 ppm."
12. A crystal form according to claim 1 wherein said form is form O.
13. A crystal form according to claim 1 wherein said form is form P.
14. A crystal form according to claim 1 wherein said form is form Q.
15. A crystal form according to claim 1 wherein said form is form R and is further characterized as having a 13C solid state NMR spectrum having a peaks with chemical shifts of about 177.9 ppm, 103.6 ppm, 95.3 ppm, 10.3 ppm, 9.6 ppm, 8.9 16 ppm, and 8.6 ppm.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29256501P | 2001-05-22 | 2001-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200308341B true ZA200308341B (en) | 2004-10-27 |
Family
ID=34115151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200308341A ZA200308341B (en) | 2001-05-22 | 2003-10-27 | Crystal Forms of Azithromycin. |
Country Status (5)
Country | Link |
---|---|
CN (1) | CN100354294C (en) |
EC (1) | ECSP034861A (en) |
GT (1) | GT200200093A (en) |
UA (1) | UA74887C2 (en) |
ZA (1) | ZA200308341B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102911219A (en) * | 2011-08-03 | 2013-02-06 | 山东方明药业集团股份有限公司 | Method for directly crystallizing azithromycin in aqueous phase |
CN105030704B (en) * | 2015-06-29 | 2018-09-07 | 石药集团欧意药业有限公司 | Azithromycin and preparation method thereof |
CN105061528B (en) * | 2015-08-05 | 2017-10-17 | 浙江维康药业股份有限公司 | A kind of azithromycin compound and the Azithromycin soft capsules containing the compound |
CN106188177A (en) * | 2016-07-12 | 2016-12-07 | 浙江亚太药业股份有限公司 | The preparation method of a kind of azithromycin compound and pharmaceutical preparation thereof |
CN111170959A (en) * | 2019-12-30 | 2020-05-19 | 南开大学 | Crystal form of macrolide compound, preparation method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1093370A (en) * | 1993-12-10 | 1994-10-12 | 北京市集才药物研究所 | A kind of new azido erythromycin crystal and preparation method thereof |
-
2002
- 2002-01-05 UA UA20031110541A patent/UA74887C2/en unknown
- 2002-05-01 CN CNB028104935A patent/CN100354294C/en not_active Expired - Fee Related
- 2002-05-21 GT GT200200093A patent/GT200200093A/en unknown
-
2003
- 2003-10-27 ZA ZA200308341A patent/ZA200308341B/en unknown
- 2003-11-21 EC ECSP034861 patent/ECSP034861A/en unknown
Also Published As
Publication number | Publication date |
---|---|
UA74887C2 (en) | 2006-02-15 |
GT200200093A (en) | 2003-05-23 |
CN1780847A (en) | 2006-05-31 |
CN100354294C (en) | 2007-12-12 |
ECSP034861A (en) | 2004-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6977243B2 (en) | Crystal forms of azithromycin | |
AU2002256846A1 (en) | Crystal Forms of Azithromycin | |
ZA200308341B (en) | Crystal Forms of Azithromycin. | |
EP1671979B1 (en) | New Cristal Form of Azithromycin | |
CA2536914C (en) | Crystal forms of azithromycin | |
US20020061856A1 (en) | Novel tricyclic erythromycin derivatives | |
US6258785B1 (en) | Crystalline 9-E-(O-methyl)oxime of 11, 12-dideoxy-3-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyloxy)-6-O-methyl-12,11-(iminocarbonyl-(2-(3-(4-(3-pyridinyl)1H-imadazol-1-yl)propyl)hydrazono))-3-oxoerythromycin |